Maze Therapeutics, Inc IPOs Tomorrow, Here's What You Need To Know
Maze Therapeutics, Inc MAZE IPO will take place January, 31 on the NASDAQ exchange under the ticker MAZE. The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider lock-up period of 180 days ending on July 30, 2025.
Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...
A Quick Take On Maze Therapeutics, Inc. Maze Therapeutics, Inc. (MAZE) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information. The ...
Jan 7 (Reuters) - Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its paperwork for a U.S. initial public offering (IPO ...
Maze Therapeutics has filed for an initial public offering with the Securities and Exchange Commission. The San Francisco-based human genetics biotech company didn't say Tuesday how many shares it ...
Maze Therapeutics looks to steer lead kidney disease assets through the clinic with $115M series D Maze also hopes to use the IPO to boost its Compass platform, which uses human genetic ...
Maze Therapeutics is eyeing a $113 million initial public offering a little under two months after revealing a $115 million ...
The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...
Formed in 2019, Sionna's most recent financing was a $182 million third round that closed last year, which followed a $111 ...
Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback